Drop in PSA screening linked to increase in metastatic prostate cancer
Targeted elimination of leukemic stem cells
16 February 2021Study examines variation in intensity of fracture-associated prescription drug use
16 February 2021Drop in PSA screening linked to increase in metastatic prostate cancer
(HealthDay)—Reductions in prostate-specific antigen (PSA) screening are associated with increases in the incidence of metastatic prostate cancer at diagnosis, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held virtually from Feb. 11 to 13.
